N. Nakamura

发表

Multiple regression analysis of sixteen risk factors including serum apolipoproteins in angiographically documented coronary artery disease.

K. Ichinose, T. Yano, N. Nakamura, 1987, Japanese circulation journal.

Effect of simultaneous infusion of a somatostatin analogue, insulin and glucose on serum triglycerides and blood glucose levels in man.

H. Kishikawa, M. Sakakida, N. Nakamura, 1985, Endocrinologia japonica.

A kindred of familial combined hyperlipidemia (FCHL) with proband showing type V hyperlipoproteinemia.

N. Nakamura, H. Uzawa, S. Kobori, 1986, Japanese journal of medicine.

Polymorphisms of apolipoprotein C-III in two cases with sialidase deficiency.

I. Goto, N. Nakamura, H. Uzawa, 1981, Life sciences.

Physical fitness. Its contribution to serum high density lipoprotein.

N. Nakamura, H. Uzawa, H. Maeda, 1983, Atherosclerosis.

Its Contribution to Serum High Density Lipoprotein

N. Nakamura, H. Uzawa, H. Maeda, 1983 .

Increased platelet phospholipase activity in diabetic subjects.

N. Nakamura, H. Uzawa, H. Takeda, 1981, Thrombosis research.

Role of α2-Adrenergic Receptor in Platelet Activation During Insulin-Induced Hypoglycemia in Normal Subjects

H. Kishikawa, M. Sakakida, K. Ichinose, 1987, Diabetes.

[Inhibitory effects of somatostatin analog (SMS 201-995) on pancreatic hormones in patients with malignant islet-cell carcinoma].

E. Araki, T. Shirotani, H. Kishikawa, 1988, Nihon Naibunpi Gakkai zasshi.

Influence of apolipoprotein E polymorphism on plasma lipid and apolipoprotein levels, and clinical characteristics of type III hyperlipoproteinemia due to apolipoprotein E phenotype E2/2 in Japan.

M. Shichiri, N. Nakamura, H. Uzawa, 1988, Atherosclerosis.

Effects of plasmapheresis on familial type III hyperlipoproteinemia associated with glomerular lipidosis, nephrotic syndrome and diabetes mellitus.

S. Fukuda, N. Nakamura, H. Uzawa, 1990, Atherosclerosis.